Klaus Schollmeier is an advisor to the Pharma/Biotech industry and member of the board of several Biotech companies.

Mr Schollmeier was Chief Executive Officer of SuppreMol, Munich/Germany from 2013 until 2015, when the company was sold to Baxalta. Prior to that, he served as CEO of Santhera, Basel/Switzerland, from 2004 to 2011 and chairman of the board of Santhera until 2013. Mr Schollmeier joined Graffinity Pharmaceuticals AG, Heidelberg/Germany as CEO in 2003 and merged the company with MyoContract AG, Basel/Switzerland in 2004 to form Santhera.

Prior to joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Ludwigshafen, Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA (from 1989 to 1993). His business functions included general manager of BASF Pharma Netherlands from 1996 to 1998 and vice president and general manager for Western Europe thereafter. From 1994 to 1995, he led BASF’s acquisition and integration of Boots Pharmaceuticals.

Mr Schollmeier holds a PhD in biology from the University of Düsseldorf, Germany, and in 1991, he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.

Contact

  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:
Top

This website uses cookies to ensure you get the best experience on our website.